Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 124Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Head and Neck Neoplasms 34Breast Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

pembrolizumab 3Nivolumab 2vicriviroc 1relatlimab 1copanlisib 1binimetinib 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Spinocerebellar Degenerations × pembrolizumab × Clear all
NCT04098068 2025-03-30

Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
12 enrolled 12 charts

Spinocerebellar Degenerations

NCT03374254 2024-11-21

KEYNOTE-651

Merck Sharp & Dohme LLC

Phase 1 Completed
116 enrolled 18 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03631407 2024-11-21

MK-7690-046

Merck Sharp & Dohme LLC

Phase 2 Completed
41 enrolled 20 charts
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡